Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355.
CAS
PubMed
PubMed Central
Google Scholar
Marrone, K. A., Ying, W., & Naidoo, J. (2016). Immune-related adverse events from immune checkpoint inhibitors. Clinical Pharmacology and Therapeutics, 100(3), 242–251.
CAS
PubMed
Google Scholar
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. The New England Journal of Medicine, 378(2), 158–168.
CAS
PubMed
Google Scholar
Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016). Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA Oncology, 2(10), 1346–1353.
PubMed
Google Scholar
U.S. Department of Health and Human Services N.I.H., National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE) version 5.0. p https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Google Scholar
Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., et al. (2014). Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute, 106(9), dju244.
PubMed
PubMed Central
Google Scholar
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y. C., & Beer, T. M. (2004). How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. Journal of Clinical Oncology, 22(17), 3485–3490.
PubMed
Google Scholar
Di Maio, M., Basch, E., Bryce, J., & Perrone, F. (2016). Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nature Reviews. Clinical Oncology, 13(5), 319–325.
PubMed
Google Scholar
U.S. Department of Health and Human Services Food and Drug Administration F.D.A. (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims.
Google Scholar
Atkinson, T. M., Ryan, S. J., Bennett, A. V., Stover, A. M., Saracino, R. M., Rogak, L. J., et al. (2016). The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer, 24(8), 3669–3676.
PubMed
PubMed Central
Google Scholar
Basch, E. (2017). Patient-reported outcomes - harnessing patients’ voices to improve clinical care. The New England Journal of Medicine, 376(2), 105–108.
PubMed
Google Scholar
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, b2700.
PubMed
PubMed Central
Google Scholar
Donald L Patrick, Gordon H Guyatt, Catherine Acquadro, & on behalf of the Cochrane Patient Reported Outcomes Methods Group (2011) Chapter 17: patient-reported outcomes. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011], (The Cochrane Collaboration).
Brahmer, J. R., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A., et al. (2017). Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): A multicentre, international, randomised, open-label phase 3 trial. The Lancet Oncology, 18(12), 1600–1609.
CAS
PubMed
Google Scholar
Mazieres, J., Kowalski, D., Luft, A., Vicente, D., Tafreshi, A., Gumus, M., et al. (2020). Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer. Journal of Clinical Oncology, 38(3), 271–280.
PubMed
Google Scholar
Reck, M., Brahmer, J., Bennett, B., Taylor, F., Penrod, J. R., DeRosa, M., et al. (2018). Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. European Journal of Cancer, 102, 23–30.
CAS
PubMed
Google Scholar
Reck, M., Taylor, F., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H., et al. (2018). Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study. Journal of Thoracic Oncology, 13(2), 194–204.
CAS
PubMed
Google Scholar
Reck, M., Schenker, M., Lee, K. H., Provencio, M., Nishio, M., Lesniewski-Kmak, K., et al. (2019). Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. European Journal of Cancer, 116, 137–147.
CAS
PubMed
Google Scholar
Spigel, D. R., McCleod, M., Jotte, R. M., Einhorn, L., Horn, L., Waterhouse, D. M., et al. (2019). Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153). Journal of Thoracic Oncology, 14(9), 1628–1639.
CAS
PubMed
Google Scholar
Barlesi, F., Garon, E. B., Kim, D. W., Felip, E., Han, J. Y., Kim, J. H., et al. (2019). Health-related quality of life in KEYNOTE-010: A phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. Journal of Thoracic Oncology, 14(5), 793–801.
CAS
PubMed
Google Scholar
Hui, R., Ozguroglu, M., Villegas, A., Daniel, D., Vicente, D., Murakami, S., et al. (2019). Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet Oncology, 20(12), 1670–1680.
CAS
PubMed
Google Scholar
Bordoni, R., Ciardiello, F., von Pawel, J., Cortinovis, D., Karagiannis, T., Ballinger, M., et al. (2018). Patient-reported outcomes in OAK: a phase III study of Atezolizumab versus docetaxel in advanced non-small-cell lung cancer. Clinical Lung Cancer, 19(5), 441–449 e444.
CAS
PubMed
Google Scholar
Bauml, J. M., Mick, R., Ciunci, C., Aggarwal, C., Davis, C., Evans, T., et al. (2019). Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncology, 5, 1283–1290.
PubMed Central
PubMed
Google Scholar
Mansfield, A. S., Kazarnowicz, A., Karaseva, N., Sanchez, A., De Boer, R., Andric, Z., et al. (2020). Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Annals of Oncology, 31(2), 310–317.
CAS
PubMed
Google Scholar
Schadendorf, D., Larkin, J., Wolchok, J., Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., et al. (2017). Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 82, 80–91.
PubMed
PubMed Central
Google Scholar
Schadendorf, D., Dummer, R., Hauschild, A., Robert, C., Hamid, O., Daud, A., et al. (2016). Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 67, 46–54.
CAS
PubMed
Google Scholar
Coens, C., Suciu, S., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., et al. (2017). Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. The Lancet Oncology, 18, 393–403.
CAS
PubMed
PubMed Central
Google Scholar
Revicki, D. A., van den Eertwegh, A. J., Lorigan, P., Lebbe, C., Linette, G., Ottensmeier, C. H., et al. (2012). Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes, 10, 66.
PubMed
PubMed Central
Google Scholar
Petrella, T. M., Robert, C., Richtig, E., Miller Jr., W. H., Masucci, G. V., Walpole, E., et al. (2017). Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. European Journal of Cancer, 86, 115–124.
CAS
PubMed
Google Scholar
Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., et al. (2016). Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study. Annals of Oncology, 27(10), 1940–1946.
CAS
PubMed
PubMed Central
Google Scholar
Cella, D., Grunwald, V., Nathan, P., Doan, J., Dastani, H., Taylor, F., et al. (2016). Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. The Lancet Oncology, 17(7), 994–1003.
CAS
PubMed
PubMed Central
Google Scholar
Cella, D., Grunwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P., et al. (2019). Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. The Lancet Oncology, 20(2), 297–310.
CAS
PubMed
PubMed Central
Google Scholar
McGregor, B. A., McKay, R. R., Braun, D. A., Werner, L., Gray, K., Flaifel, A., et al. (2020). Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. Journal of Clinical Oncology, 38(1), 63–70.
PubMed
Google Scholar
O'Donnell, P. H., Arkenau, H. T., Sridhar, S. S., Ong, M., Drakaki, A., Spira, A. I., et al. (2020). Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer, 126(2), 432–443.
CAS
PubMed
Google Scholar
Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., et al. (2018). Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. Journal of Clinical Oncology, 36(16), 1579–1587.
CAS
PubMed
Google Scholar
Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., et al. (2017). Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. Journal of Clinical Oncology, 35(19), 2125–2132.
CAS
PubMed
PubMed Central
Google Scholar
von Tresckow, B., Fanale, M., Ardeshna, K. M., Chen, R., Meissner, J., Morschhauser, F., et al. (2019). Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leukemia & Lymphoma, 60(11), 2705–2711.
Google Scholar
Harrington, K. J., Ferris, R. L., Blumenschein Jr., G., Colevas, A. D., Fayette, J., Licitra, L., et al. (2017). Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. The Lancet Oncology, 18, 1104–1115.
CAS
PubMed
PubMed Central
Google Scholar
Ferris, R. L., Blumenschein Jr., G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., et al. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 375(19), 1856–1867.
PubMed
PubMed Central
Google Scholar
Kaufman, H. L., Hunger, M., Hennessy, M., Schlichting, M., & Bharmal, M. (2018). Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncology, 14(3), 255–266.
CAS
PubMed
Google Scholar
Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M. J., Oaknin, A., Kerger, J., et al. (2019). Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, 37(31), 2825–2834.
CAS
PubMed
PubMed Central
Google Scholar
Bharmal, M., Fofana, F., Barbosa, C. D., Williams, P., Mahnke, L., Marrel, A., et al. (2017). Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health and Quality of Life Outcomes, 15(1), 247.
PubMed
PubMed Central
Google Scholar
King-Kallimanis, B. L., Howie, L. J., Roydhouse, J. K., Singh, H., Theoret, M. R., Blumenthal, G. M., et al. (2019). Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. Clinical Trials, 16(3), 322–326.
PubMed
Google Scholar
Hall, E. T., Singhal, S., Dickerson, J., Gabster, B., Wong, H.-N., Aslakson, R. A., et al. (2019). Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care - a systematic review. Journal of Pain and Symptom Management, 58(1), 137–156.e131.
PubMed
Google Scholar
European Medicines Agency E.M.A. (2016) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies.
Google Scholar
Brundage, M., & Hanna, T. (2017). Adjuvant ipilimumab for stage III melanoma: the patient voice. The Lancet Oncology, 18(3), 282–284.
PubMed
Google Scholar
Lorigan, P., & Green, A. C. (2017). Immunotherapy: does adjuvant ipilimumab have little adverse effect on quality of life? Nature Reviews. Clinical Oncology, 14(7), 395–396.
CAS
PubMed
Google Scholar
Singer, S. (2017). Quality of life after nivolumab treatment for head and neck cancer. The Lancet Oncology, 18(8), 993–994.
PubMed
Google Scholar
Das, S., & Horn, L. (2017). Quality matters: Immunotherapy and the evolving landscape of advanced cancer care. Expert Review of Quality of Life in Cancer Care, 2(5), 235–244.
Google Scholar
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., et al. (2017). Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunology Research, 5(4), 312–318.
PubMed
PubMed Central
Google Scholar
El Osta, B., Hu, F., Sadek, R., Chintalapally, R., & Tang, S. C. (2017). Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Critical Reviews in Oncology/Hematology, 119, 1–12.
PubMed
Google Scholar
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017). Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology, 28(10), 2377–2385.
CAS
PubMed
Google Scholar
Kluetz, P. G., Slagle, A., Papadopoulos, E. J., Johnson, L. L., Donoghue, M., Kwitkowski, V. E., et al. (2016). Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research, 22(7), 1553–1558.
CAS
PubMed
Google Scholar
Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., et al. (2010). The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology, 63(11), 1179–1194.
PubMed
PubMed Central
Google Scholar
Kulis, D., Bottomley, A., Whittaker, C., van de Poll-Franse, L. V., Darlington, A., Holzner, B., et al. (2017). The use of the Eortc item library to supplement Eortc quality of life instruments. Value in Health, 20(9), A775.
Google Scholar
Petersen, M. A., Groenvold, M., Aaronson, N. K., Chie, W. C., Conroy, T., Costantini, A., et al. (2011). Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension. Quality of Life Research, 20(4), 479–490.
PubMed
Google Scholar
Hansen, A. R., Ala-Leppilampi, K., McKillop, C., Siu, L. L., Bedard, P. L., Abdul Razak, A. R., et al. (2020). Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 126(7), 1550–1558.
PubMed
Google Scholar
Kyte, D., Retzer, A., Ahmed, K., Keeley, T., Armes, J., Brown, J. M., et al. (2019). Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials. Journal of the National Cancer Institute, 111, 1170–1178.
PubMed
PubMed Central
Google Scholar
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology magnitude of clinical benefit scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573.
CAS
PubMed
Google Scholar
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., et al. (2016). Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. Journal of Clinical Oncology, 34(24), 2925–2934.
PubMed
Google Scholar